ESMA EROĞLU
Anatolian Current Medical Journal - 2021;3(2):185-187
Dermatological diseases may be the only early clinical manifestation of liver disease for patients. It has been shown that at least one skin manifestation develops in approximately 17% of chronic HCV infection patients. Dermatological manifestations have also been seen with antiviral therapy for HCV. It is difficult to distinguish that cutaneous adverse reactions are associated with antiviral therapy or cutaneous manifestations of HCV. Interferonfree direct-acting antiviral (DAA) therapies in the chronic hepatitis C virus (HCV) infections have low side effects. Sofosbuvir/ribavirin (SOF/RBV) therapy combination is among in the currently approved treatment regimens. Alopecia areata is a very rare side effect of this treatment. A case of alopecia areata developed after SOF/RBV combination therapy in a patient with chronic hepatitis C infection is presented.
